FT. MYERS, Fla.,
Jan. 11, 2011
/PRNewswire/ -- NeoGenomics, Inc. (NASD OTC Bulletin Board: NGNM)
announced today that it has been notified that the Qui Tam complaint filed against it and several other healthcare companies in 2009 has been voluntarily dismissed with prejudice by the relator in the case. As a result, no further action will be taken against NeoGenomics in this matter.
, the Company's Chairman and CEO, stated, "We are pleased, but not surprised that this case has been dismissed. NeoGenomics constantly strives to operate with impeccable integrity and at the highest standards of conduct in our industry. After a year of review by the U.S. Attorney's office, this case was dismissed with prejudice. Frivolous lawsuits like this are costly to government and businesses, and divert management attention from growth, job creation, and improving our health care system. Reform is needed to eliminate incentives to file lawsuits with unfounded complaints in pursuit of 'Jackpot Justice'. The plaintiff in this case should be ashamed of his actions and should be made to publicly apologize to the defendants and reimburse them for the legal expenses."
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in
Fort Myers, FL
, NeoGenomics has labs in
and services the needs of pathologists, oncologists, urologists, and hospitals throughout
the United States
. For additional information about NeoGenomics, visit
For more news and information on NeoGenomics, please visit
where you can find a fact sheet on the company, investor presentations, and more. Interested parties can also access additional investor relations material, including an investment profile and an equity research report, from Hawk Associates at
or from the American Microcap Institute at
SOURCE NeoGenomics, Inc.